Fluorizoline|cas:1362243-70-6|西域试剂

Fluorizoline,99.77%

产品编号：Bellancom-114989| CAS NO：1362243-70-6| 分子式：C₁₅H₈Cl₂F₃NS| 分子量：362.20

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-114989	￥900.00	杭州北京（现货）
Bellancom-114989	￥1700.00	杭州北京（现货）
Bellancom-114989	￥3500.00	杭州北京（现货）
Bellancom-114989	￥5500.00	杭州北京（现货）
Bellancom-114989	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Fluorizoline

产品介绍

Fluorizoline 选择性地直接结合到 prohibitin 1 (PHB1) 和 2 (PHB2)，并诱导凋亡。Fluorizoline 通过上调 NOXA 和 BIM 降低慢性淋巴细胞性白血病 (CLL) 细胞的活力。Fluorizoline 以 p53 非依赖性方式发挥抗肿瘤作用。

生物活性

Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner.

体外研究

Fluorizoline (1.25-20 μM; 24 hours) induces apoptosis in primary CLL cells ex vivo.
Fluorizoline (5-10 μM; 48 hours) causes an increase of NOXA protein levels.
Fluorizoline reduces the percentage of viable normal B and T cells (48.6% and 82.8% of viable cells at 24 hours of treatment with 10 μM Fluorizoline in normal CD19⁺ and CD3⁺ populations, respectively) with mean EC₅₀ values of 10.9 μM and 19.1 μM at 24 hours for normal B and T cells, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	Primary CLL cells
Concentration:	1.25 to 20 μM
Incubation Time:	24 hours
Result:	Strongly reduced cell viability and induced apoptosis in a dose-dependent manner.

Western Blot Analysis

Cell Line:	Primary CLL cells
Concentration:	5, 10 μM
Incubation Time:	48 hours
Result:	Caused an increase of NOXA protein levels.

体内研究
(In Vivo)

Fluorizoline (15 mg/kg; ip; three times a week for five weeks) becomes very rapidly (3 weeks) leukemic, as reflected by the increase in the percentage and the number of CD5⁺CD19⁺ CLL cells in the blood in 6-week-old recipient C57BL/6 Eμ-TCL1 mouse model of CLL. Fluorizoline does not induce apoptosis in vivo. Fluorizoline does not control disease development in the spleen as indicated by enlarged spleens.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (138.05 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7609 mL	13.8045 mL	27.6091 mL
5 mM	0.5522 mL	2.7609 mL	5.5218 mL
10 mM	0.2761 mL	1.3805 mL	2.7609 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.5 mg/mL (6.90 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (6.90 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (6.90 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (6.90 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.90 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。